Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Total Non-Current Liabilities (2019 - 2025)

Historic Total Non-Current Liabilities for Madrigal Pharmaceuticals (MDGL) over the last 14 years, with Q3 2025 value amounting to $345.3 million.

  • Madrigal Pharmaceuticals' Total Non-Current Liabilities rose 19199.24% to $345.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $345.3 million, marking a year-over-year increase of 19199.24%. This contributed to the annual value of $118.6 million for FY2024, which is 164.66% up from last year.
  • Madrigal Pharmaceuticals' Total Non-Current Liabilities amounted to $345.3 million in Q3 2025, which was up 19199.24% from $122.9 million recorded in Q2 2025.
  • In the past 5 years, Madrigal Pharmaceuticals' Total Non-Current Liabilities registered a high of $345.3 million during Q3 2025, and its lowest value of $283000.0 during Q1 2022.
  • Over the past 5 years, Madrigal Pharmaceuticals' median Total Non-Current Liabilities value was $99.2 million (recorded in 2023), while the average stood at $85.5 million.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first plummeted by 2687.34% in 2022, then skyrocketed by 2956961.13% in 2023.
  • Quarter analysis of 5 years shows Madrigal Pharmaceuticals' Total Non-Current Liabilities stood at $387000.0 in 2021, then soared by 12636.18% to $49.3 million in 2022, then soared by 136.7% to $116.7 million in 2023, then increased by 1.65% to $118.6 million in 2024, then soared by 191.19% to $345.3 million in 2025.
  • Its last three reported values are $345.3 million in Q3 2025, $122.9 million for Q2 2025, and $118.8 million during Q1 2025.